CA19-9/ Sialyl Lewis a (sialyted lacto-N-fucopentose) (α-NeuNAc-(2→3)-β-D-Gal-(1→3)-(α-L-Fuc-[1→4])-D-GlcNAc, 3′-SLea) corresponds to blood group antigens.
In normal tissue Sialyl Lewis a is present in ductal epithelium of the breast, kidney and salivary glands.
This antigen is expressed is increased in all gastrointestinal carcinomas (stomach, intestine and pancreas).
While it is not useful to diagnose particular forms of cancer, specifically pancreatic cancer, it may be useful to monitor the results of treatment and to determine whether the disease may be recurring.
Other causes for elevated CA19-9 levels include Mirizzi’s syndrome and other hepatobiliary diseases.
In patients that do not have the Lewis antigen blood type (about 5% of the population), CA19-9 is not elevated in pancreatic cancer even with large tumors because they have a deficiency of fucosyltransferase that is needed to produce CA19-9 .
Applications:Suitable for use in Western Blot, ELISA, Immunohistochemistry and Immunocytochemistry.
Other applications not tested.
Recommended Dilutions:Immunohistochemistry: 1:200Western Blot: 1:1000 -1:5000Immunocytochemistry: 1:200Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4℃ for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20℃.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：100ul
抗体種類：Mab
宿主：mouse
Source Antibody：human
Grade：Affinity Purified
Purity：Purified by Protein A affinity chromatography from hybridoma culture.
Form：Supplied as a liquid in PBS, pH 7.4, 0.05% sodium azide.
